The Epothilones: New Therapeutic Agents for Castration-Resistant Prostate Cancer

The Oncologist, 10/21/2011

Clinical activity has been observed in nonrandomized trials for patients with CRPC using ixabepilone in the first– and second–line settings as a single agent and in combination with estramustine. Patupilone and sagopilone were also shown to have promising efficacy in phase II clinical trials of patients with CRPC. All three epothilones appear to be well tolerated, with modest rates of neutropenia and peripheral neuropathy. The lack of crossresistance between epothilones and taxanes may allow sequencing of these agents. Evaluating epothilones in phase III comparative trials would provide much–needed insight into their potential place in the management of patients with CRPC.

Print Article Summary Cat 2 CME Report